6,499
Views
18
CrossRef citations to date
0
Altmetric
Research Article

Pharmacologic Safety Concerns in Parkinson's Disease: Facts and Insights

Pages 45-52 | Received 01 Apr 2011, Published online: 31 Oct 2011

REFERENCES

  • Chen JJ, Obering C. Apomorphine in the management of motor fluctuations associated with Parkinson's disease. Clin Ther. 2005;27:1710–24
  • Apokyn [package insert]. Brisbane, CA: Ipsen; 2010.
  • Arnold G, Schwarz J, Macher C, Oertel WH. Domperidone is superior to ondansetron in acute apomorphine challenge in previously untreated parkinsonian patients—a double blind study. Parkinsonism Relat Disord. 1997 Dec;3(4):191–3.
  • Olanow CW, Watkins PB. Tolcapone: an efficacy and safety review (2007). Clin Neuropharmacol. 2007;30:287–94.
  • Assal F, Spahr L, Hadengue A, Rubbia-Brandt L, Burkhard PR. Tolcapone and fulmanant hepatitis. Lancet. 1998;352: 958.
  • Olanow CW, Tasmar Advisory Panel. Tolcapone and hepatotoxic effects. Arch Neurol. 2000;57:263–7.
  • Haasio K. Toxicology and safety of COMT inhibitors. Int Rev Neurobiol. 2010;95:163–89.
  • Korri H, Awada A. Serious tolpcapone-induced hepatitis 17 months after commencing treatment. Rev Neurol (Paris). 2005 Nov;161:1113–5.
  • Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52:1908–10.
  • Knie B, Mitra MT, Logishetty K, Chaudhuri KR. Excessive daytime sleepiness in patients with Parkinson's disease. CNS Drugs. 2011;25:203–12.
  • Rye DB. Excessive daytime sleepiness and unintended sleep in Parkinson's disease. Curr Neurol Neurosci Rep. 2006;6: 169–76.
  • Manni R, Terzaghi M, Sartori I, Mancini F, Pacchetti C. Dopamine agonists and sleepiness in PD: review of the literature and personal findings. Sleep Med. 2004;5:189–93.
  • Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson's disease. JAMA. 2002;287:455–63.
  • Ambermoon P, Carter A, Hall WD, Dissanayaka NN, O'Sullivan JD. Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Addiction. 2010;106:283–93.
  • Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE. Impulse control disorders in Parkinson's disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67:589–95.
  • Lim SY, Evans AH, Miyasaki JM. Impulse control and related disorders in Parkinson's disease: review. Ann NY Acad Sci. 2008;1142:85–107.
  • Potenza MN, Voon V, Weintraub D. Drug insight: impulse control disorders and dopamine therapies in Parkinson's disease. Nat Clin Pract Neurol. 2007;3:664–72.
  • American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders—text revision (DSM-IV-TR). Washington, DC: APA; 2000.
  • Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, Duda JE, Moberg PJ, Stern MB. Association of dopamine agonist use with impulse control disorders in Parkinson's disease. Arch Neurol. 2006;63:969–73.
  • Dang D, Cunnington D, Swieca J. The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome. Clin Neuropharmacol. 2011;34:66–70.
  • Cornelius JR, Tippmann-Peikert M, Slocumb NL, Frerichs CF, Silber MH. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep. 2010;33:81–7.
  • Bermejo PE. Topiramate in managing impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord. 2008;14:448–9.
  • Bermejo PE, Ruiz-Huete C, Anciones B. Zonisamide in managing impulse control disorders in Parkinson's disease. J Neurol. 2010;257:1682–5.
  • Ceravolo R, Frosini D, Rossi C, Bonuccelli U. Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord. 2009;15(Suppl 4):S111–5.
  • Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112–20.
  • Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. Q J Med J. 2003;96:635–42.
  • Quinn DK, Stern TA. Linezolid and serotonin syndrome. Prim Care Companion J Clin Psychiatry. 2009;11(6):353–6.
  • Oates JA, Sjoerdsma A. Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology. 1960;10:1076078.
  • Richard IH, Kurlan R, Tanner C, Factor S, Hubble J, Suchowersky O, Waters C. Parkinson Study Group. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology. 1997;48:1070–77.
  • Sanyal D, Chakraborty S, Bhattacharyya R. An interesting case of serotonin syndrome precipitated by escitalopram. Indian J Pharmacol. 2010;42:418–9.
  • Hinds NP, Hillier CEM, Wiles CM. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. J Neurol. 2000;247:811.
  • Bilbao Garay J, Mesa Plaza N, Castilla Castellano V, Dhimes Tejada P. Serotonin syndrome: report of a fatal case and review of the literature. Rev Clin Esp. 2002;202:209–11.
  • Gitlin MJ. Venlafaxine, monoamine oxidase inhibitors, and the serotonin syndrome. J Clin Psychopharmacol. 1997;17:66–7.
  • http://www.pharmgkb.org/search/annotatedGene/cyp2c19 (Accessed May 23, 2011)
  • Harvey AT, Preskorn SH. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. J Clin Psychopharmacol. 2001 Apr;21(2):161–6.
  • Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol. 1996;51:73–8.
  • Fernandes C, Prashanth R, Kessel B. Rasagiline-induced serotonin syndrome. Mov Disord. 2011;26:766–7.
  • Chen JJ, Swope DM, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther. 2007;29:1825–49.
  • Panisset M, Schwid S, Ondo W, Fitzer-Attas C, Chen JJ. Safety of concomitant therapy with rasagiline and antidepressants in Parkinson's disease. Mov Disord. 2007;223(Suppl 16):S104–5.
  • Montgomery EB, Panisset M. Retrospective analysis of the incidence of serotonin toxicity in patients taking rasagiline and antidepressants in clinical trials. Mov Disord. 2009;24(Suppl 1):359.
  • Ghosh P, Winslow J, Musleh C, Gandhy C, Bahroo L, Pagan F. The tolerability of rasagiline when used concurrently with serotonin reuptake inhibitors in Parkinson's disease: a retrospective analysis. Mov Disord. 2010;25(Suppl 2):S400.
  • Chhabria N, Ghosh P, Bahroo L, Pagan F. A “real world” view of the tolerability of rasagiline with anti-depressants in Parkinson's disease: a retrospective study. Neurology. 2011;76(Suppl 4):A485–6.
  • Panisett M, Chen JJ, Rhyee SH. Assessing the occurrence of serotonin toxicity in Parkinson's disease patients receiving rasagiline and antidepressants. Neurology. 2011;76(Suppl 4):A539.
  • Hilli J, Korhonen T, Laine K. Lack of clinically significant interactions between concomitantly administered rasagiline and escitalopram. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1526–32.
  • Keegan MT, Brown DR, Rabinstein AA. Serotonin syndrome from the interaction of cyclobenzaparine with other serotoninergic drugs. Anesth Analg. 2006;103:1466–8.
  • Schwartz AR, Pizon AF, Brooks DE. Dextromethorphan-induced serotonin syndrome. Clin Toxicol (Phila). 2008;46:771–3.
  • Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis. 2006;42:1578–83.
  • Rivers N, Horner B. Possible lethal reaction between nardil and dextromethorphan. Can Med Assoc J. 1970;103:85.
  • Sovner R, Wolfe J. Interaction between dextromethorphan and monoamine oxidase inhibibitor therapy with isocarboxazid. N Engl J Med. 1988;319:1671.
  • Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005;95:434–41.
  • Asch DA, Parker RM. The Libby Zion case: one step forward or two steps backward? N Engl J Med. 1988;318:771–5.
  • Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and selegiline. Lancet. 1991; 337(8735):246.
  • Karunatilake H, Buckley NA. Serotonin syndrome induced by fluvoxamine and oxycodone. Ann Pharmacother. 2006;40:155–7.
  • Rosebraugh CJ, Flockhart DA, Yasuda SU, Woosley RL. Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient. J Clin Pharmacol. 2001;41:224–7.
  • Reich M, Lefebvre-Kuntz D. Serotoninergic antidepressants and opiate analgesics: a sometimes-painful association. A case report. Encephale. 2010;36(Suppl 2):D119–23.
  • Kirschner R, Donovan JW. Serotonin syndrome precipitated by fentanyl during procedural sedation. J Emerg Med. 2010;38:477–80.
  • Rang ST, Field J, Irving C. Serotonin toxicity caused by an interaction between fentanyl and paroxetine. Can J Anaesth. 2008;55:521–5.
  • Nathan, PJ. Hypericum perforatum (St John's Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology. J Psychopharmacol. 2001;15:47–54.
  • McGrath PJ, Stewart JW, Quitkin FM. A possible L-deprenyl induced hypertensive reaction. J Clin Psychopharmacol. 1989;9:310–11.
  • Chen JJ, Wilkinson JR. The monoamine oxidase type-B inhibitor rasagiline in the treatment of Parkinson's disease: Is tyramine a challenge? J Clin Pharmacol. 2011 May 31 (Epub ahead of print).
  • Goren T, Adar L, Sasson N, Weiss YM. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase inhibitor type B (MAO-B) inhibitor rasagiline. J Clin Pharmacol. 2010;50:1420–8.
  • de Marcaida JA, Schwid SR, White WB, Blindauer K, Fahn S, Kieburtz K, Stern M, Shoulson I; the Parkinson Study Group TEMPO, PRESTO Tyramine Substudy Investigators and Coordinators. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord. 2006;21:1716–21.
  • Wilkinson J, Reichwein S, Stern M. Safety and tolerability of tyramine challenge in levodopa-treated Parkinson's disease (PD) patients receiving rasagiline. Presented at American Academy of Neurology Annual Meeting; 2008 Apr 12-19; Chicago, IL.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.